Skip to main content

Table 1 Participant characteristics

From: Mild hyponatremia is associated with low skeletal muscle mass, physical function impairment, and depressive mood in the elderly

 

n

Mild hyponatremia group

n

Normonatremia group

p

Age, years

75

82.0 (76.0–84.0)

2907

79.0 (75.0–83.0)

0.03

Female, n (%)

75

36 (48.0)

2907

1833 (63.1)

0.008

Education, years

75

9.0 (9.0–12.0)

2869

9.0 (9.0–12.0)

0.8

Heavy drinkera, n (%)

74

1 (1.4)

2879

55 (1.9)

0.7

Body mass index, kg/m2

75

21.0 (19.1–23.6)

2905

21.8 (19.8–24.0)

0.09

History of cardiac disease, n (%)

75

15 (20.0)

2907

365 (12.6)

0.06

History of diabetes, n (%)

75

36 (48.0)

2907

1049 (36.1)

0.03

History of liver disease, n (%)

75

1 (1.3)

2907

61 (2.1)

0.6

History of lung disease, n (%)

75

4 (5.3)

2907

119 (4.1)

0.6

History of depression, n (%)

75

2 (2.7)

2907

106 (3.6)

0.7

History of CKD, n (%)

75

33 (44.0)

2905

1006 (34.6)

0.1

History of cancer, n (%)

75

9 (12.0)

2907

240 (8.3)

0.2

Dementia, n (%)

75

45 (60.0)

2907

1516 (52.1)

0.2

Joint pain, n (%)

74

31 (41.9)

2890

1173 (40.6)

0.8

Visual impairment, n (%)

74

37 (50.0)

2888

1607 (55.6)

0.4

Hearing impairment, n (%)

74

47 (63.5)

2883

1524 (52.9)

0.07

Diuretics use, n (%)

75

6 (8.0)

2907

129 (4.4)

0.1

Antibiotics, n (%)

75

0 (0.0)

2907

34 (1.2)

0.3

Proton pump inhibitor use, n (%)

75

6 (8.0)

2907

208 (7.2)

0.8

NSAID or acetaminophen use, n (%)

75

4 (5.3)

2907

127 (4.4)

0.7

Antiepileptic use, n (%)

75

2 (2.7)

2907

11 (0.4)

0.003

Antipsychotic use, n (%)

75

0 (0.0)

2907

17 (58.5)

0.5

NaSSA use, n (%)

75

1 (1.3)

2907

6 (0.2)

0.05

SSRI or SNRI use, n (%)

75

5 (6.7)

2907

51 (1.8)

0.002

Benzodiazepine use, n (%)

75

12 (16.0)

2907

254 (8.7)

0.03

Inactivity, n (%)

74

21 (28.4)

2864

957 (33.4)

0.4

Potassium, mEq/L

75

4.4 (4.1–4.6)

2907

4.2 (2.9–4.4)

<  0.001

Calcium, mg/dL

75

9.4 (9.1–9.7)

2901

9.5 (9.2–9.8)

0.4

BNP, pg/mL

38

30.1 (16.5–64.9)

1562

31.8 (16.3–60.2)

0.9

eGFR, mL/min/1.73m2

75

62.1 (52.2–80.9)

2905

63.3 (54.0–73.2)

0.6

CRP, mg/dL

74

0.07 (0.04–0.2)

2881

0.05 (0.03–0.1)

0.02

Anemiab, n (%)

75

10 (13.3)

2907

195 (6.7)

0.03

Hypothyroidismc, n (%)

75

2 (2.7)

2898

10 (0.3)

0.002

Vitamin B12 deficiencyd, n (%)

63

1 (1.6)

2535

59 (2.3)

0.7

  1. Values are median (interquartile range) or number (percentage). Differences were assessed using the Kruskal–Wallis test for continuous variables or the Chi-squared test for categorical variables
  2. Abbreviations: BNP Brain natriuretic peptide, CRP C-reactive protein, eGFR Estimated glomerular filtration rate, NSAID Non-steroidal anti-inflammatory drug, NaSSA Noradrenergic and specific serotonergic antidepressant, SNRI Serotonin noradrenaline reuptake inhibitor, SSRI Selective serotonin reuptake inhibitors. a > 60 g/day of alcohol, bHemoglobin < 11.0 g/dL, cthyroid-stimulating hormone ≤10μIU/mL, dvitamin B12 < 200 pg/mL